Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04061941
Other study ID # BDF180058
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 21, 2019
Est. completion date December 31, 2023

Study information

Verified date May 2024
Source The University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In Hong Kong, methamphetamine use is common and cocaine use has increased steadily over the past few years. While the use of ketamine decreased from 35.8% in 2015 to 13.9% in 2017, methamphetamine and cocaine have become the most commonly used psychotropic substances and account for more than 50% of drug abuses cases in 2017. Among all stimulants, methamphetamine is most commonly used because it releases three times more dopamine than cocaine and the effects can last from eight to twelve hours, compared to two hours for cocaine. On top of its extreme effects, methamphetamine is relatively inexpensive, making it even more accessible to the young population. Misuse of methamphetamine has long been associated with profound psychological and cognitive disturbance. In reviewing the cognitive data from reasonably well-matched groups of chronic methamphetamine users and healthy controls, the majority of studies have found that chronic methamphetamine users had lower scores on at least some cognitive tests, although some studies are exceptions with entirely nonsignificant differences. A meta-analysis of 17 cross-sectional studies found that chronic methamphetamine users demonstrated significantly lower cognitive scores than healthy controls. The effects were largest for measures of learning, executive functions, memory, and processing speed, although the majority of cognitive domains significantly differed between the groups. Concerns has been emerging regarding the methodology of the aforementioned results. In particular, the appropriateness of using healthy controls to examine the cognitive effects of stimulant use has been questioned. Much of the published research has fallen victim to using controls with significant baseline differences from the chronic stimulant users, such as years of education. In addition, none of the studies available provided scatter plots of their cognitive data to evaluate the overlap in performance between chronic stimulant users and healthy controls. In fact, many chronic stimulant users have normal cognitive function when compared with normative data. Therefore, the use of the term 'impairment' or 'deficit' in many studies is not fully justified. Another limitation is that it cannot differentiate cognitive weaknesses that may predate stimulant use from those that result from it. Notably, longitudinal studies have shown that childhood deficits in executive function can predict drug abuse in adolescence, suggesting that at least some of the cognitive weaknesses pre-exist in chronic stimulant user. These and other limitations provoked a conclusion that the evidence for cognitive deficits in chronic stimulant users is weak. In order to overcome the methodological issues observed in previous cross-sectional studies, we propose to conduct a prospective studies to determine the change in cognitive function among stimulant users over time.


Recruitment information / eligibility

Status Completed
Enrollment 93
Est. completion date December 31, 2023
Est. primary completion date May 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age: 18 - 65 years old at the time of enrolment - Able to read and communicate in English and/or Chinese - Able to give informed consent - Using stimulants as the primary psychoactive substance of abuse - "Repeated" and "Active" stimulant users as defined by Structured Clinical Interview for DSM-5 Disorders (SCID-5) Exclusion Criteria: - Age <18 years old - Unable to read English or Chinese - Unable to give informed consent - Had been diagnosed with other Substance Use or Related Disorders with severity =4 according to DSM-5, or other psychoactive substance dependence syndrome according to International Classification of Disease (ICD-10) - Currently taking regular prescribed psychiatric medications, including antipsychotics, antidepressants, mood stabilizers, anti-epileptics, benzodiazepines, hypnotics, and anti-cholinergic medications. - Had been diagnosed with other DSM-5 disorders including: - Neurodevelopmental Disorders - Schizophrenia Spectrum and Other Psychotic Disorders - Bipolar and Related Disorders - Depressive Disorders, Anxiety Disorders, and Obsessive-Compulsive and Related Disorders - Dissociative Disorders, Somatic Symptoms and Related Disorders - Feeding and Eating Disorders - Sleep-wake Disorders - Neurocognitive Disorders

Study Design


Intervention

Behavioral:
Cognitive Assessment
Assessment on cognitive dysfunction using standardised cognitive tests

Locations

Country Name City State
Hong Kong Queen Mary Hospital Hong Kong

Sponsors (2)

Lead Sponsor Collaborator
The University of Hong Kong Beat Drugs Fund Association

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Montreal Cognitive Assessment Measure the change in global cognitive function 12 months
Primary Frontal Assessment Battery Measure the change in executive function 12 months
Primary Diagnostic and Statistical Manual of mental disorders 5th edition (DSM-5 )severity of stimulant use disorder To determine different severity of stimulant use 12 months
Secondary Frequency of stimulant use 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05806840 - Rapid Adaptation to Prevent Drug Use N/A
Recruiting NCT06003725 - Cultural Adaptation of Drug Treatment for DJJ Youth N/A
Recruiting NCT05414344 - A Brief Intervention for Alcohol Users With Interpersonal Trauma N/A
Recruiting NCT05768815 - Optimizing Mental Health for Infants Exposed to Early Adversity: A Comparison of Breaking the Cycle and Maxxine Wright N/A
Completed NCT05606601 - An Online Intervention Addressing Mental Health and Substance Use in University Students N/A
Completed NCT03489434 - Technology-Based Prevention for Adolescents in Primary Care N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT02990026 - Specialty Mental Health Probation in North Carolina N/A
Not yet recruiting NCT06116266 - Collaborative Care for Polysubstance Use in Primary Care Settings (Co-Care) N/A
Not yet recruiting NCT03249428 - E-Cigarette Inner City RCT N/A
Active, not recruiting NCT03129334 - Preventing Prescription Drug Abuse in Middle School Students N/A
Completed NCT04183400 - Safety Awareness For Empowerment (SAFE): An RCT With Young People Experiencing Homelessness N/A
Completed NCT02112201 - The ProGirls Study N/A
Completed NCT01752998 - Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings N/A
Terminated NCT01661517 - Brief Intervention and Referral to Treatment With Substance Use Disorders in the Emergency Room Setting Phase 0
Completed NCT01351454 - Behavioral Depression Treatment for African American HIV-infected Substance Users N/A
Completed NCT01511380 - Targeting HIV Risk Behaviors in Juvenile Drug Court-Involved Youth Phase 2
Completed NCT01154309 - Group CBT for Depression and AOD Disorders Phase 1
Completed NCT00996541 - Support To Reunite Involve and Value Each Other N/A